Rapid re-expression of CD133 protein in colorectal cancer cell lines in vitro and in vivo

Laboratory Investigation

Volumn 92, Issue 11, 2012, Pages 1607-1622

  Peickert, Susann ^a   Waurig, Julia ^a   Dittfeld, Claudia ^a   Dietrich, Antje ^a   Garbe, Yvette ^a   Kabus, Lydia ^a   Baumann, Michael ^a,b   Grade, Marian ^c   Ried, Thomas ^d   Kunz Schughart, Leoni A ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

2 D culture; 3 D culture; cancer stem cell hypothesis; CD133 protein; colorectal cancer cell line; radio chemotherapy; xenograft

Indexed keywords

CD133 ANTIGEN; FLUOROURACIL; OXALIPLATIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CARCINOGENICITY; CELL DENSITY; CELL GROWTH; CELL POPULATION; CELL STRAIN HCT116; CELL STRAIN HT29; CELL SUBPOPULATION; CELL SURFACE; CELL SURVIVAL; COLONY FORMATION; COLORECTAL CANCER; CONTROLLED STUDY; DRUG RESPONSE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PLASTICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION RESPONSE; TUMOR ENGRAFTMENT; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTIGENS, CD; COLORECTAL NEOPLASMS; FEMALE; GLYCOPROTEINS; HCT116 CELLS; HT29 CELLS; HUMANS; MICE; NEOPLASMS, EXPERIMENTAL; PEPTIDES; TUMOR MARKERS, BIOLOGICAL;

EID: 84868576953     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2012.124     Document Type: Article

References (66)

1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010;46: 765-781.
2. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-2917.
3. Schmiegel W, Pox C, Reinacher-Schick A, et al. S3 guidelines for colorectal carcinoma: results of an evidence-based consensus conference on February 6/7, 2004 and June 8/9, 2007 (for the topics IV, VI and VII). Z Gastroenterol 2010;48:65-136.
4. Rodel C, Arnold D, Becker H, et al. Induction chemotherapy before chemoradiotherapy and surgery for locally advanced rectal cancer: is it time for a randomized phase III trial?. Strahlenther Onkol 2010; 186:658-664.
5. Todaro M, Francipane MG, Medema JP, et al. Colon cancer stem cells: promise of targeted therapy. Gastroenterology 2010;138:2151-2162.
6. Hermann PC, Bhaskar S, Cioffi M, et al. Cancer stem cells in solid tumors. Semin Cancer Biol 2010;20:77-84.
7. Woodward WA, Sulman EP. Cancer stem cells: markers or biomarkers?. Cancer Metastasis Rev 2008;27:459-470.
8. Shipitsin M, Polyak K. The cancer stem cell hypothesis: in search of definitions, markers, and relevance. Lab Invest 2008;88:459-463. (Pubitemid 351581449)
9. Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006;66:9339-9344. (Pubitemid 44623625)
10. Neuzil J, Stantic M, Zobalova R, et al. Tumour-initiating cells vs. cancer 'stem' cells and CD133: what's in the name?. Biochem Biophys Res Commun 2007;355:855-859. (Pubitemid 46366906)
11. Boman BM, Wicha MS. Cancer stem cells: a step toward the cure. J Clin Oncol 2008;26:2795-2799.
12. Huang EH, Wicha MS. Colon cancer stem cells: implications for prevention and therapy. Trends Mol Med 2008;14:503-509.
13. O'Brien CA, Kreso A, Dick JE. Cancer stem cells in solid tumors: an overview. Semin Radiat Oncol 2009;19:71-77.
14. Ricci-Vitiani L, Pagliuca A, Palio E, et al. Colon cancer stem cells. Gut 2008;57:538-548. (Pubitemid 351442540)
15. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008;8:755-768.
16. Dalerba P, Dylla SJ, Park IK, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 2007; 104:10158-10163. (Pubitemid 47175279)
17. Du L, Wang H, He L, et al. CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res 2008;14:6751-6760.
18. Haraguchi N, Ohkuma M, Sakashita H, et al. CD133\+CD44\+ population efficiently enriches colon cancer initiating cells. Ann Surg Oncol 2008;15:2927-2933.
19. O'Brien CA, Pollett A, Gallinger S, et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007;445:106-110. (Pubitemid 46067310)
20. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007;445: 111-115. (Pubitemid 46067311)
21. Dittfeld C, Dietrich A, Peickert S, et al. CD133 expression is not selective for tumor-initiating or radioresistant cell populations in the CRC cell line HCT-116. Radiother Oncol 2010;94:375-383.
22. Ieta K, Tanaka F, Haraguchi N, et al. Biological and genetic characteristics of tumor-initiating cells in colon cancer. Ann Surg Oncol 2008;15:638-648. (Pubitemid 351643025)
23. Kawamoto H, Yuasa T, Kubota Y, et al. Characteristics of CD133(\+) human colon cancer SW620 cells. Cell Transplant 2010;19: 857-864.
24. Ghadimi BM, Sackett DL, Difilippantonio MJ, et al. Centrosome amplification and instability occurs exclusively in aneuploid, but not in diploid colorectal cancer cell lines, and correlates with numerical chromosomal aberrations. Genes Chromosomes Cancer 2000;27: 183-190. (Pubitemid 30030317)
25. Friedrich J, Seidel C, Ebner R, et al. Spheroid-based drug screen: considerations and practical approach. Nature Protocols 2009;4: 309-324.
26. Dallas NA, Xia L, Fan F, et al. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulinlike growth factor-I receptor inhibition. Cancer Res 2009;69: 1951-1957.
27. Sgambato A, Errico F, Caredda E, et al. Divergent expression of CD133 in different studies: The need for a consensus panel?. Int J Cancer 2011;128:2247-2249.
28. Mariotti E, Gemei M, Mirabelli P, et al. The percentage of CD133\+ cells in human colorectal cancer cell lines is influenced by Mycoplasma hyorhinis infection. BMC Cancer 2010;10:120.
29. Elsaba TM, Martinez-Pomares L, Robins AR, et al. The stem cell marker CD133 associates with enhanced colony formation and cell motility in colorectal cancer. PLoS One 2010;5:e10714.
30. Botchkina GI, Zuniga ES, Das M, et al. New-generation taxoid SB-T-1214 inhibits stem cell-related gene expression in 3D cancer spheroids induced by purified colon tumor-initiating cells. Mol Cancer 2010; 9:192.
31. Baumann M, Krause M, Thames H, et al. Cancer stem cells and radiotherapy. Int J Radiat Biol 20091-12.
32. Gaiser T, Camps J, Meinhardt S, et al. Genome and transcriptome profiles of CD133-positive colorectal cancer cells. Am J Pathol 2011;178:1478-1488.
33. Horst D, Kriegl L, Engel J, et al. CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer 2008;99:1285-1289.
34. Kojima M, Ishii G, Atsumi N, et al. CD133 expression in rectal cancer after preoperative chemoradiotherapy. Cancer Sci 2010;101:906-912.
35. Horst D, Kriegl L, Engel J, et al. CD133 and nuclear beta-catenin: the marker combination to detect high risk cases of low stage colorectal cancer. Eur J Cancer 2009;45:2034-2040.
36. Horst D, Kriegl L, Engel J, et al. Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer. Cancer Invest 2009;27:844-850.
37. Wang Q, Chen ZG, Du CZ, et al. Cancer stem cell marker CD133\+ tumour cells and clinical outcome in rectal cancer. Histopathology 2009;55:284-293.
38. Li CY, Li BX, Liang Y, et al. Higher percentage of CD133\+ cells is associated with poor prognosis in colon carcinoma patients with stage IIIB. J Transl Med 2009;7:56.
39. Takahashi S, Kamiyama T, Tomaru U, et al. Frequency and pattern of expression of the stem cell marker CD133 have strong prognostic effect on the surgical outcome of colorectal cancer patients. Oncol Rep 2010;24:1201-1212.
40. Ong CW, Kim LG, Kong HH, et al. CD133 expression predicts for nonresponse to chemotherapy in colorectal cancer. Mod Pathol 2010;23: 450-457.
41. Horst D, Scheel SK, Liebmann S, et al. The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer. J Pathol 2009;219: 427-434.
42. Saigusa S, Tanaka K, Toiyama Y, et al. Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. Ann Surg Oncol 2009;16:3488-3498.
43. Saigusa S, Tanaka K, Toiyama Y, et al. Clinical significance of CD133 and hypoxia inducible factor-1alpha gene expression in rectal cancer after preoperative chemoradiotherapy. Clin Oncol (R Coll Radiol) 2011; 23:323-332.
44. Saigusa S, Tanaka K, Toiyama Y, et al. Immunohistochemical features of CD133 expression: association with resistance to chemoradiotherapy in rectal cancer. Oncol Rep 2010;24:345-350.
45. Yasuda H, Tanaka K, Saigusa S, et al. Elevated CD133, but not VEGF or EGFR, as a predictive marker of distant recurrence after preoperative chemoradiotherapy in rectal cancer. Oncol Rep 2009;22: 709-717.
46. Shmelkov SV, Butler JM, Hooper AT, et al. CD133 expression is not restricted to stem cells, and both CD133\+ and CD133-metastatic colon cancer cells initiate tumors. J Clin Invest 2008;118:2111-2120.
47. Heeschen C, Huber S, Hermann PC. CD133 in cancer stem cells revisited. J Clin Invest 2008;118:2111.
48. Wu Y, Wu PY. CD133 as a marker for cancer stem cells: progresses and concerns. Stem Cells Dev 2009;18:1127-1134.
49. LaBarge MA, Bissell MJ. Is CD133 a marker of metastatic colon cancer stem cells?. J Clin Invest 2008;118:2021-2024. (Pubitemid 351872322)
50. Kemper K, Sprick MR, de Bree M, et al. The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res 2010;70:719-729.
51. Navarro-Alvarez N, Kondo E, Kawamoto H, et al. Isolation and propagation of a human CD133(r) colon tumor-derived cell line with tumorigenic and angiogenic properties. Cell Transplant 2010;19: 865-877.
52. Bidlingmaier S, Zhu X, Liu B. The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells. J Mol Med 2008; 86:1025-1032.
53. Corbeil D, Roper K, Fargeas CA, et al. Prominin: a story of cholesterol, plasma membrane protrusions and human pathology. Traffic 2001; 2:82-91. (Pubitemid 32219860)
54. Miraglia S, Godfrey W, Yin AH, et al. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 1997;90:5013-5021. (Pubitemid 28007218)
55. Shmelkov SV, Jun L, St Clair R, et al. Alternative promoters regulate transcription of the gene that encodes stem cell surface protein AC133. Blood 2004;103:2055-2061. (Pubitemid 38326220)
56. Corbeil D, Roper K, Hellwig A, et al. The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. J Biol Chem 2000;275: 5512-5520. (Pubitemid 30115186)
57. Taieb N, Maresca M, Guo XJ, et al. The first extracellular domain of the tumour stem cell marker CD133 contains an antigenic gangliosidebinding motif. Cancer Lett 2009;278:164-173.
58. Liao Y, Hu X, Huang X, et al. Quantitative analyses of CD133 expression facilitate researches on tumor stem cells. Biol Pharm Bull 2010;33: 738-742.
59. Platet N, Liu SY, Atifi ME, et al. Influence of oxygen tension on CD133 phenotype in human glioma cell cultures. Cancer Lett 2007;258: 286-290. (Pubitemid 350110377)
60. Blazek ER, Foutch JL, Maki G. Daoy medulloblastoma cells that express CD133 are radioresistant relative to CD133 cells, and the CD133\+ sector is enlarged by hypoxia. Int J Radiat Oncol Biol Phys 2007;67:1-5. (Pubitemid 44959518)
61. Griguer CE, Oliva CR, Gobin E, et al. CD133 is a marker of bioenergetic stress in human glioma. PLoS One 2008;3:e3655.
62. McCord AM, Jamal M, Shankavaram UT, et al. Physiologic oxygen concentration enhances the stem-like properties of CD133\+ human glioblastoma cells in vitro. Mol Cancer Res 2009;7:489-497.
63. Brunner TB, Kunz-Schughart LA, Grosse-Gehling P, et al. Cancer stem cells as a predictive factor in radiotherapy. Semin Radiat Oncol 2012; 22:151-174.
64. Sgambato A, Errico F, Caredda E, et al. Divergent expression of CD133 in different studies: the need for a consensus panel?. Int J Cancer 2011;128:2247-2249.
65. Yeung TM, Gandhi SC, Wilding JL, et al. Cancer stem cells from colorectal cancer-derived cell lines. Proc Natl Acad Sci USA 2010; 107:3722-3727.
66. Kemper K, Grandela C, Medema JP. Molecular identification and targeting of colorectal cancer stem cells. Oncotarget 2010;1:387-395.